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Nitric oxide (NO) plays an important role as a leishmanicidal agent in murine macrophages. NO resistant
Escherichia coli and Mycobacterium tuberculosis have been associated with poor outcomes of their result-
ing diseases. NO resistant Leishmania braziliensis has also been identiﬁed and exacerbates the clinical
course of human leishmaniasis. We report, for the ﬁrst time, natural resistance of Leishmania chagasi
promastigotes to NO. These parasites were isolated from humans and dogs with visceral leishmaniasis.
We also demonstrate that this resistance proﬁle was associated with a greater survival capacity and a
greater parasite burden in murine macrophages, independent of activation and after activation by IFN-
c and LPS.
 2012 Elsevier Inc. Open access under the Elsevier OA license.Background
Visceral leishmaniasis (VL) is a systemic disease that is the most
severe form of leishmaniasis. It presents with high morbidity, lead-
ing to death if not adequately treated. The disease is caused by
Leishmania chagasi, a protozoa that infects dogs and human. The
protozoa are transmitted to mammalian hosts by the bite from
an infected sand ﬂy vector of the genus Lutzomya, which inoculates
parasites in the host skin, where they undergo facilitated phagocy-
tosis by macrophage. In these phagocytes the promastigotes trans-
form into obligate intracellular amastigotes [1,2]. Some individuals
infected with L. chagasi may remain asymptomatic, while others
develop the classical form of visceral leishmaniasis [3], presenting
with symptoms including fever, hepatosplenomegaly, and
hyperglobulinemia.
The activation of the oxidative responses by the production of
reactive intermediates of oxygen and nitrogen are the major hostIC50, half maximal inhibitory
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evier OA license.defense mechanisms against intracellular pathogens [4]. NO resis-
tant Mycobacterium tuberculosis have been described and are
associated with a more severe disease outcome [5]. Natural resis-
tance to NO was also demonstrated in Leishmania amazonensis
and Leishmania braziliensis, that cause cutaneous and mucosal
leishmaniasis in humans [6]. Indeed, genotype and phenotype vari-
ations of Leishmania spp. can be associated with the large spectrum
of tegumentary disease in humans. In previous work, the NO resis-
tant parasites were demonstrated to cause larger cutaneous lesions
than NO susceptible parasites [6,7].
Although visceral leishmaniasis is a more homogeneous
phenotype, some variation in disease severity has been observed
[8]. Since the susceptibility of L. chagasi to nitric oxide has not
been tested, we decided to evaluate the viability of L. chagasi in
the presence of NO and compare the infective capacity of these
isolates. We showed the existence of naturally resistant prom-
astigotes of L. chagasi from humans and dogs, and that these
resistant proﬁles can augment their infective capacity in murine
macrophages.Methods
Initially, we evaluated the viability of L. chagasi to NO, once clas-
siﬁed as resistant and susceptible to NO, we compared their infec-
tive capacity in J774 murine macrophages.
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L. chagasi promastigotes were obtained from bone marrow aspi-
rates from both visceral leishmaniasis patients and the canine res-
ervoirs. The patients were recruited at the University Hospital of
Federal University of Sergipe, where they receive treatment for
VL. The dogs were recruited at the Center for Zoonosis Control
(CCZ) in Aracaju-SE and they all presented with positive serology
for VL. The local Ethics Committee approved all procedures used
in this study (CAAE 0151.0.107.000–07, Hospital Universitário,
Universidade Federal de Sergipe (UFS) for humans; and 96/2011,
Comitê de Ética em Pesquisa Animal/UFS for animals).
Parasite isolates from humans (n = 21) and dogs (n = 21) were
initially cultivated in tubeswith biphasicmedium (NNN) consisting
of rabbit blood agar overlaidwith Schneider’s insectmedium(Sigma
Chemical Co., St. Louis, MO, USA), supplemented with 10% heat-
inactivated fetal bovine serum medium (Sigma Chemical Co., St.
Louis, MO). Following isolation, parasite isolates were cryopre-
served. A samplewas used to speciate in our laboratory by polymer-
ase chain reaction with primers speciﬁc for Leishmania infantum
RV1–50 CTT TTC TGG TCC CGC GGG TAG G 30 e RV2 – CCA CCT GGC
CTA TTT TAC ACC A 30 [9] and also sent to the Department of Bio-
chemistry andMolecular Biology at the InstitutoOswaldo Cruz, FIO-
CRUZ, Rio de Janeiro, Brazil [10]. The time of storage of the selected
parasites was similar (p > 0.05). The parasites selected for study had
not been previously passaged in liquid culture medium before the
beginning of the present study. After selection, the promastigotes
were expanded in Schneider’s insect medium (Sigma Chemical Co.,
St. Louis, MO, USA) pH 7.2, supplementedwith 10% heat-inactivated
fetal bovine serum (FBS) and 100 U/ml of penicillin/streptomycin.
Viability assay of L. chagasi promastigotes to NaNO2
To evaluate the viability of L. chagasi to NO we followed the pro-
tocol proposed by Giudice and colleagues [6]. Promastigotes in log-
arithmic growth phase were adjusted to 5  107 parasites/ml in
Hanks’ balanced solution (HBSS) (Sigma Chemical Co., St. Louis,
MO, USA) pH 5.0 and distributed in 96-well plates (U-bottom) in ali-
quots of 100 ll, containing106parasites perwell. Theparasiteswere
exposed to dilutions of NaNO2 (Sigma Chemical Co., St. Louis, MO,
USA), pH 5.0 (NO donor) from 0 to 16 mM during 4 h incubation at
25 C. For assess the viability, we use the MTT assay described in
the section ‘‘MTT assay’’. We consider resistant to NO the parasites
with a survival below 70% at 16 mM NaNO2 concentration.
Viability assay of L. chagasi promastigotes to SNAP
L. chagasi promastigotes in logarithmic growth phase were
adjusted to 5  106 parasites/ml in Schneider and distributed in
96-well plates (U-bottom) in aliquots of 100 ll, containing 105
parasites per well. The parasites were exposed to dilutions of SNAP
(12–1125 lM) (Invitrogen., Eugene, OR, USA) previously incubated
at 24 C for 24 h[11]. To assess the viability, we used the MTT assay
as described in the section ‘‘MTT assay’’.
MTT assay
After incubation with different NO donors, the plates were cen-
trifuged (700g for 10 min). The supernatants were removed by cen-
trifugation and parasite viability was measured by MTT assay as
previously described[12]. Brieﬂy, plates were incubated in 100 ll
of Hanks solution, pH 7.0 plus 10 ll of MTT (5 mg/ml) [3-(4,5-
dimetthythiazol-2-yl)-2,5-diphenyltetiazolium bromide] (Sigma
Chemical Co., St. Louis, MO, USA) at 25 C for 4 h, followed by addi-
tion of 100 ll 0.04 N HCl in isopropanol to stop the reaction. Living
mitochondria convert MTT to dark blue formazan, which is solublein acid-isopropanol and detectable on a microplate reader at
492 nm. The percentage of viability was calculated from (OD),
which is due to incorporation of MTT by the parasites. For each
parasite isolate, three experiments at least were performed to test
for NO susceptibility.
Maintenance of J774 murine macrophages
The J774 murine macrophage cell line was maintained at 37 C,
5% CO2 in RPMI medium (Sigma Chemical Co., St. Louis, MO, USA)
containing 10% (vol/vol) fetal bovine serum (Sigma Chemical Co.,
St. Louis, MO, USA) and 1% penicillin antibiotic (Sigma Chemical
Co., St. Louis, MO, USA).
L. chagasi infection of J774 murine macrophages
We tested the infectivity of the NO resistant and NO susceptible
L. chagasi promastigotes in murine macrophage cell line J774.
These macrophages were detached from the tissue culture ﬂasks
by gentle scraping with a cell scraper. J774 cells (1  105/well)
were distributed in eight-well Labtek chambers and allowed to ad-
here overnight prior to infection. J774 cells were kept without
stimulus or stimulated with INF-c (20 ng/ml) (Sigma Chemical
Co., St. Louis, MO, USA) plus LPS (100 ng/ml) (Sigma Chemical
Co., St. Louis, MO, USA) for two hours prior to infection. Four NO
resistant and four NO susceptible promastigotes in logarithmic
growth phase were maintained at 25 C in Schneider’s insect med-
ium (Sigma Chemical Co., St. Louis, MO, USA) pH 7.2 supplemented
with 10% fetal bovine serum (FBS) (Sigma Chemical Co., St. Louis,
MO, USA). For each isolates, two to three independent experiments
were performed, and all experiments were performed in duplicate.
Parasites were cultured for 5 days until transform in stationary
phase promastigotes. They were then centrifuged (700g for
10 min). Supernatants were discarded, and the pellets were resus-
pended in RPMI-1640 and washed three times by centrifugation.
After overnight adherence, macrophages were infected with sta-
tionary – phase promastigotes at a parasite/macrophage ratio of
5:1 for 2 h at 37 C in 5% CO2. Extracellular parasites were removed
by gentle washing and infected macrophages were maintained for
an additional 24, 48 and 72 h. Cells were stained with Panoptico
fast (LaborClin, PR, BRA) and the infection levels were evaluated
by counting the number of infected cells and the number of para-
sites per 100 macrophages by three independent observers,
blinded to the experimental conditions.
Statistical analysis
Mann–Whitney test was used to compare the number NO sus-
ceptible and resistant parasites after exposure to different concen-
trations of NaNO2 and SNAP. This test was also used to compare the
number of infected macrophages and numbers of L. chagasi/100
cells between NO susceptible and resistant parasites at each time
after infection. IC50 was calculated by nonlinear regression analysis.
Spearman’s rank correlation method was used for correlation anal-
ysis between IC50 and number amastigotes/100 macrophages at
72 h of infection of three independent experiments These analyses
were done on GraphPad Prism 5.0 software (San Diego, CA, USA).Results
Isolates of L. chagasi from humans and canine showed natural
resistance to nitric oxide (NO)
Promastigotes were exposed to increasing concentrations of
NaNO2 (0–16 mM) and viability was determined by the MTT
Table 1
Comparison of minimum inhibitory concentration that eliminates 50% of the parasites
(IC50) of the L. chagasi isolates to different NO donors, NaNO2 and SNAP.
L. chagasi R.If p valueg
Resistant Susceptible
NaNO2a (mM) IC50b 193.2 ± 217.4 9.3 ± 7.5 21 0.0001
n (Rc = 25; Sd = 17)
SNAPe (lM) IC50b 48776 ± 81465 636.0 ± 282.2 76 0.0022
n (Rc=3; Sd=3)
a Sodium nitrite.






P.L. Santos et al. / Nitric Oxide 27 (2012) 67–71 69colorimetric method. We found that 12 L. chagasi isolated from hu-
mans were considered resistant to NO, showing an average of 87%
survival at 16 mM NaNO2, while nine isolates were considered sus-
ceptible to NO, showing an average of 50% survival at concentra-
tions of 8 mM (Fig. 1A). The average IC50 (50% inhibitory
concentration) was 165.9 mM NaNO2 for the resistant isolates, as
compared to 13.3 mM NaNO2 for the susceptible isolates
(p = 0.01, Mann–Whitney test).
13 L. chagasi promastigotes isolated from dogs were also consid-
ered resistant to NO, showing an average of 100% survival at
16 mM NaNO2, while eight isolates were considered susceptible
to NO, showing an average of 50% survival at concentrations of
2 mM (Fig. 1B). The average IC50 was 238.7 mM NaNO2 for the
resistant isolates, as compared to 4.8 mM NaNO2 for the suscepti-
ble isolates (p = 0.01, Mann–Whitney test).
We conﬁrmed the survival to nitric oxide using another NO
donor, SNAP. Promastigotes of L. chagasi obtained from dogs and
humans were incubated with increasing concentrations of SNAP
(12–1125 lM) for 24 h and their viability measured by MTT color-
imetric assay. The proﬁle of NO resistance of both dogs and hu-
mans L. chagasi was conﬁrmed, showing an IC50 of 193.2 mM for
NaNO2 and of 48,8 lM for SNAP, as compared to the NO suscepti-
ble L. chagasiwith an IC50 of 9.3 mM for NaNO2 and of 636.0 lM for
SNAP (Table 1).Survival of naturally NO resistant L. chagasi is greater in the J774
murine macrophages cell line
To evaluate whether the NO resistance phenotype would en-
hance the infectivity and survival of amastigote in macrophages,
we selected four resistant (LVHSE 9 and 14) and four susceptible
(LVHSE 7 and 17) isolates from humans and infected J774 murine
macrophages. We followed the infection after 2, 24, 48 and 72 h.
We observed that after 2 h both resistant and susceptible isolates
presented similar patterns of macrophages infection (Fig. 2). Inter-
estingly, the resistant isolates survived and proliferated better in
murine macrophages, showing a signiﬁcantly higher number ofFig. 1. Survival of L. chagasi promastigotes in increasing concentrations of nitric
oxide. Log phase L. chagasi (1  106/ml) were exposed for 4 h to increasing
concentrations of NaNO2, (0.25–16 mM) at 25 C in Hanks’ solution pH 5.0. Viability
was determined by MTT colorimetric assay. A: L. chagasi from human patients
(resistant, n = 12; susceptible, n = 9) and B: dogs (resistant, n = 13; susceptible,
n = 8) with visceral leishmaniasis.infected macrophages and parasite numbers at 72 h post infection
(Fig. 2A and B, p < 0.05). These differences were even more clear
after we activated the microcidal activity of the macrophages with
IFN-c plus LPS, which increased the ability of the macrophages to
control the multiplication of the NO susceptible isolates, but not
the ability to control the infection of the NO resistant isolates
(Fig. 2C and D) (p < 0.05).
The greater survival of the resistant isolates was further con-
ﬁrmed by correlation analysis, which showed a correlation be-
tween the IC50 of NaNO2 and the number of amastigotes/100
macrophages at 72 h post infection (Spearman r = 0.690; p = 0.03)
(Fig. 3).Discussion
We describe here, for the ﬁrst time, the existence of L. chagasi
naturally resistant to nitric oxide isolated from humans and dogs.
This resistance was demonstrated in promastigostes using two
NO donors, NaNO2 and SNAP, with 21 and 76 folds increase of
IC50, respectively, at the highest concentrations of these two
compounds.
Previously, Mauel and Ransijn [13] have shown that promastig-
otes and amastigotes of Leishmania enriettii and Leishmania major
were susceptible to NO, using different NO donors, and describe
some of the targets of NO in the parasite biochemical pathways.
Holzmuller and colleagues [14], have successfully induced
in vitro NO resistance in L. infantum. Natural resistance to NO has
been described in species that cause cutaneous and mucosal leish-
maniasis [6,15].
We also demonstrated that the resistance proﬁles enhances the
survival and proliferation of amastigotes in the J774 murine mac-
rophages cell line. The infectivity of the NO susceptible and resis-
tant isolates are similar, as demonstrated by their similar
abilities to infect macrophage at 2 h post infection, but the increas-
ing numbers of parasites and numbers of infected macrophages
after 72 h post infection in the NO resistant parasites clearly show
their resistance to macrophage’s microbicidal mechanisms, even
after activation with IFN-c and LPS. In fact, the increase of the
IC50 was correlated with higher number of amastigotes in macro-
phages at 72 h post infection, conﬁrming the inﬂuence of NO resis-
tance in parasite survival. Giudice and colleagues [6] had also
similar results with human macrophages infected with NO resis-
tant L. amazonensis and L. braziliensis.
The clinical consequences of infection with NO resistant para-
sites can be demonstrated in tegumentary leishmaniasis. Giudice
and colleagues [6] described that the patients infected with the
NO resistant parasites presented with lesions of larger sizes. Souza
and colleagues [15] found that L. braziliensis obtained from patients
Fig. 2. Infection of macrophage with NO resistant or susceptible L. chagasi. Murine macrophage cell line J774 was infected with NO-resistant (n = 4) or NO-susceptible (n = 4)
L. chagasi promastigotes (5:1 ratio). At 2, 24, 48 and 72 h of culture the percentage of infected cells/100 macrophages (A) and the number of intracellular amastigotes/100
macrophages (B) was quantiﬁed microscopically. (C) and (D) represents the same experiment in murine macrophage cell line J774 treated with LPS (100 ng/mL) plus IFN-c
(10 ng/mL) 2 h before the infection. The values represent the mean ± SEM from of three independent experiments from four isolates and two for the other four isolates (Total
of 20 experiments) (⁄p < 0.05, Mann–Whitney test).
Fig. 3. Correlation analysis between the IC50 and number of amastigotes/100
macrophages at 72 h of infection of three independent experiments. The IC50 value,
at which 50% of cell growth is inhibited compared with control, was calculated by
nonlinear regression analysis.
70 P.L. Santos et al. / Nitric Oxide 27 (2012) 67–71refractory to antimony treatment were more resistant to NO than
the parasites isolated from patients responding to antimony treat-
ment, with IC50 values of 2.0 and 5.8 mM NaNO2, respectively.
Ritter and colleagues [16] showed that L. major isolated from two
patients with a severe clinical course of cutaneous leishmaniasis
presented a more infective capacity in murine macrophages
in vitro. Dogs are described to present a more severe course of dis-
ease when compared with human disease [17]. In addition, dogs
show more resistance to antimony treatment, with parasite persis-
tence [18]. While these can be explained by individual characteris-
tics of these animals, for instance, nutritional factors and immune
response [19,20], our ﬁndings suggest that the NO resistance of the
L. chagasi isolated from dogs should also be investigated to help ex-
plain in part the greater severity of VL in these animals. It is inter-
esting that the NO resistance of the parasites isolated from dogs
seems even greater than the humans’ isolates. These ﬁndings can
be alerted to natural selection of parasites resistant to NO in these
animals.
In humans, although VL has a relatively homogeneous pheno-
type, differences in disease severity call the attention of clinicians.Host genetics characteristics have been associated with disease,
but not to its severity [21–24]. Carvalho and colleagues [25] have
elegantly described the inﬂuence of immune response in clinical
evolution of leishmania-infected children to VL. No studies have
yet demonstrated the inﬂuence of either host or parasite differ-
ences in VL disease severity. In this study there is no relationship
of the NO resistant isolates and disease severity, except for one iso-
late which came from a patient that is refractory to several
leishmanicidal drugs, and relapsed three times during follow-up.
However, it is important to call upon clinicians to isolate and store
the leishmania to evaluate possible associations between the par-
asites NO resistance and clinical complications in the course of VL.
In conclusion, we demonstrate the existence of L. chagasi from
humans and dogs that are naturally resistant to NO and that these
resistant isolates have a higher capacity to survive against murine
macrophages microcidal mechanisms.Financial support
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